Clinical trial: Exposure to ribavirin predicts EVR and SVR in patients with HCV genotype 1 infection treated with peginterferon alfa-2a plus ribavirin

Alimentary Pharmacology and Therapeutics

Volumn 28, Issue 1, 2008, Pages 43-50

  Bain, V G ^a,b   Lee, S S ^c   Peltekian, K ^d   Yoshida, E M ^e   Deschenes M ^f   Sherman, M ^g   Bailey, R ^h   Witt Sullivan, H ⁱ   Balshaw, R ^j   Krajden, M ^k  

^a Zeidler Ledcor Centre   (Canada)

^b UNIVERSITY OF ALBERTA   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d DALHOUSIE UNIVERSITY   (Canada)

^e VANCOUVER HOSPITAL AND HEALTH SCIENCES CENTRE   (Canada)

^f ROYAL VICTORIA HOSPITAL   (Canada)

^g UNIVERSITY HEALTH NETWORK   (Canada)

^h ROYAL ALEXANDRA HOSPITAL   (Canada)

ⁱ HAMILTON HEALTH SCIENCES   (Canada)

^j Syreon Corporation   (Canada)

^k BRITISH COLUMBIA CENTRE FOR DISEASE CONTROL   (Canada)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PEGINTERFERON ALPHA2A; RIBAVIRIN;

ADULT; ARTICLE; BODY WEIGHT; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED STUDY; DEMOGRAPHY; DRUG DOSE INCREASE; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG RESPONSE; FEMALE; GENOTYPE; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RESPONSE VARIABLE; TREATMENT DURATION; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG THERAPY, COMBINATION; FEMALE; HEPACIVIRUS; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2A; MALE; MIDDLE AGED; POLYETHYLENE GLYCOLS; RIBAVIRIN; TREATMENT OUTCOME;

EID: 44649113041     PISSN: 02692813     EISSN: 13652036     Source Type: Journal    
DOI: 10.1111/j.1365-2036.2008.03705.x     Document Type: Article

References (19)

1. Strader DB, Wright T, Thomas DL, Seeff LB. Diagnosis, management, and treatment of hepatitis C. Hepatology 2004 39 : 1147 71.
2. Dienstag JL, McHutchison JG. American Gastroenterological Association medical position statement on the management of hepatitis C. Gastroenterology 2006 130 : 225 30.
3. Management of hepatitis C. A National Clinical Guideline. Scottish Intercollegiate Guidelines Network. 2006. Available at: http://www.sign.ac.uk/ pdf/sign92.pdf (accessed 21 September 2007).
4. Sherman M, Shafran S, Burak K, et al. Management of chronic hepatitis C: Consensus guidelines. Can J Gastroenterol 2007 21 (Suppl. C 25C 34C.
5. Hadziyannis SJ, Sette H, Jr, Morgan TR, et al. Peginterferon-alpha2a and ribavirin combination therapy in chronic hepatitis C: a randomized study of treatment duration and ribavirin dose. Ann Intern Med 2004 140 : 346 55.
6. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002 347 : 975 82.
7. Davis G, Wong J, McHutchison J, Manns M, Harvey J, Albrecht J. Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis C. Hepatology 2003 38 : 645 52.
8. McHutchison JG, Manns M, Patel K, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology 2002 123 : 1061 9.
9. Reddy KR, Shiffman ML, Morgan TR, et al. Impact of ribavirin dose reductions in hepatitis C virus genotype 1 patients completing peginterferon alfa-2a/ribavirin treatment. Clin Gastroenterol Hepatol 2007 5 : 124 9.
10. Shiffman ML, Ghany MG, Morgan TR, et al. Impact of reducing peginterferon alfa-2a and ribavirin dose during retreatment in patients with chronic hepatitis C. Gastroenterology 2007 132 : 103 12.
11. Lee SS, Bain VG, Peltekian K, et al. Treating chronic hepatitis C with pegylated interferon alfa-2a (40 KD) and ribavirin in clinical practice. Aliment Pharmacol Ther 2006 23 : 397 408.
12. Sherman M, Yoshida EM, Deschênes M, et al. Peginterferon alfa-2a (40KD) plus ribavirin in chronic hepatitis C patients who failed previous interferon therapy. Gut 2006 55 : 1631 8.
13. Snoeck E, Wade JR, Duff F, Lamb M, Jorga K. Predicting sustained virological response and anaemia in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD) plus ribavirin. Br J Clin Pharmacol 2006 62 : 699 709.
14. Fried M, Jensen D, Rodriguez-Torres M, et al. Improved sustained virological response (SVR) rates with higher fixed doses of peginterferon alfa-2a (40KD) (Pegasys) plus ribavirin (RBV) (Copegus) in patients with "difficult-to-cure" characteristics [abstract no. 335]. Hepatology 2006 44 (Suppl. 1 314A.
15. Jacobson IM, Brown RS Jr, Freilich B, et al. Peginterferon alfa-2b and weight-based or flat-dose ribavirin in chronic hepatitis C patients: A randomized trial. Hepatology 2007 46 : 971 81.
16. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R. High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005 41 : 275 9.
17. Sherman M, Cohen L, Cooper MA, et al. Clinical recommendations for the use of recombinant human erythropoietin in patients with hepatitis C virus being treated with ribavirin. Can J Gastroenterol 2006 20 : 479 85.
18. Shiffman M, Salvatore J, Hubbard S, et al. Treatment of chronic hepatitis C virus genotype 1 with peginterferon, ribavirin, and epoetin alpha. Hepatology 2007 46 : 371 9.
19. Bronowicki JP, Ouzan D, Asselah T, et al. Effect of ribavirin in genotype 1 patients with hepatitis C responding to pegylated interferon alfa-2a plus ribavirin. Gastroenterology 2006 131 : 1040 8.